Clinical and bacteriologic efficacy of telithromycin in patients with bacteremic community-acquired pneumonia

被引:8
作者
Carbon, C
van Rensburg, D
Hagberg, L
Fogarty, C
Tellier, G
Rangaraju, M
Nusrat, R
机构
[1] Medpark Ctr, ZA-1035 Witbank, South Africa
[2] Sahlgrens Univ Hosp, S-41685 Gothenburg, Sweden
[3] Spartanburg Pharmaceut Res, Spartanburg, SC 29307 USA
[4] Zoom Int Clin Res Grp, St Jerome, PQ J7Z 5T3, Canada
[5] Sanofi Aventis, Romainville, France
[6] Sanofi Aventis, Bridgewater, NJ USA
关键词
telithromycin; community-acquired pneumonia; bacteremia; sepsis; ketolide; Streptococcus pneumoniae;
D O I
10.1016/j.rmed.2005.11.007
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
This retrospective analysis was performed to determine the clinical and bacteriologic efficacy of the ketolide antibacterial telithromycin in patients with community-acquired pneumonia (CAP) with pneumococcal bacteremia. Patients >= 13 years old with radiologically confirmed CAP and a positive blood culture for Streptococcus pneumoniae at screening were analyzed from eight multicenter Phase III/IV clinical trials. In four open-label, non-comparative studies, patients received telithromycin 800 mg once daily for 7-10 days. In four randomized, controlled, double-blind, comparative studies, patients received telithromycin 800mg once daily for 5-10 days or a comparator antimicrobial (amoxicillin 1000 mg three times daily, clarithromycin 500mg twice daily, or trovafloxacin 200mg once daily) for 7-10 days. In total, 118 patients (telithromycin, 94/1061 [8.9%]; comparator, 24/244 [9.8%]) had documented pneumococcal bacteremia. Those who were treated with telithromycin achieved a clinical cure rate of 90.2% (74/82, per-protocol population); S. pneumoniae was eradicated in 77/82 (93.9%) bacteremic patients who received telithromycin and 15/19 (78.9%) comparator-treated patients. Clinical cure was also observed among telithromycin-treated bacteremic patients who were infected with penicillin- or erythromycin-resistant strains of S. pneumoniae (5/7 and 8/10, respectively). In conclusion, telithromycin achieves high clinical and bacteriologic cure rates in CAP patients with pneumococcal bacteremia. (c) 2005 Published by Elsevier Ltd.
引用
收藏
页码:577 / 585
页数:9
相关论文
共 45 条
  • [11] Telithromycin 800 mg once daily for seven to ten days is an effective and well-tolerated treatment for community-acquired pneumonia
    Carbon, C
    Moola, S
    Velancsics, I
    Leroy, B
    Rangaraju, M
    Decosta, P
    [J]. CLINICAL MICROBIOLOGY AND INFECTION, 2003, 9 (07) : 691 - 703
  • [12] Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada
    Chen, DK
    McGeer, A
    de Azavedo, JC
    Low, DE
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (04) : 233 - 239
  • [13] Efficacy and tolerability of once-daily oral telithromycin compared with clarithromycin for the treatment of community-acquired pneumonia in adults
    Dunbar, LM
    Hassman, J
    Tellier, G
    [J]. CLINICAL THERAPEUTICS, 2004, 26 (01) : 48 - 62
  • [14] NEW AND EMERGING ETIOLOGIES FOR COMMUNITY-ACQUIRED PNEUMONIA WITH IMPLICATIONS FOR THERAPY - A PROSPECTIVE MULTICENTER STUDY OF 359 CASES
    FANG, GD
    FINE, M
    ORLOFF, J
    ARISUMI, D
    YU, VL
    KAPOOR, W
    GRAYSTON, JT
    WANG, SP
    KOHLER, R
    MUDER, RR
    YEE, YC
    RIHS, JD
    VICKERS, RM
    [J]. MEDICINE, 1990, 69 (05) : 307 - 316
  • [15] Detection of macrolide resistance mechanisms in Streptococcus pneumonide and Streptococcus pyogenes using a multiplex rapid cycle PCR with microwell-format probe hybridization
    Farrell, DJ
    Morrissey, I
    Bakker, S
    Felmingham, D
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2001, 48 (04) : 541 - 544
  • [16] Felmingham D, 2001, CLIN MICROBIOL INFEC, V7, P2, DOI 10.1046/j.1469-0691.2001.0070s3002.x
  • [17] Increasing prevalence of antimicrobial resistance among isolates of Streptococcus pneumoniae from the PROTEKT surveillance study, and compatative in vitro activity of the ketolide, telithromycin
    Felmingham, D
    Reinert, RR
    Hirakata, Y
    Rodloff, A
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 50 : 25 - 37
  • [18] Prognosis and outcomes of patients with community-acquired pneumonia - A meta-analysis
    Fine, MJ
    Smith, MA
    Carson, CA
    Mutha, SS
    Sankey, SS
    Weissfeld, LA
    Kapoor, WN
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 275 (02): : 134 - 141
  • [19] A prediction rule to identify low-risk patients with community-acquired pneumonia
    Fine, MJ
    Auble, TE
    Yealy, DM
    Hanusa, BH
    Weissfeld, LA
    Singer, DE
    Coley, CM
    Marrie, TJ
    Kapoor, WN
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (04) : 243 - 250
  • [20] Bacteremic pneumonia due to multidrug-resistant pneumococci in 3 patients treated unsuccessfully with azithromycin and successfully with levofloxacin
    Fogarty, C
    Goldschmidt, R
    Bush, K
    [J]. CLINICAL INFECTIOUS DISEASES, 2000, 31 (02) : 613 - 615